---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033874"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2026-05-12T11:14:36+00:00"
generated_at: "2026-05-12T11:21:48.762384+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas and Pfizer out-license VEPPANU to Rigel for $85M upfront; potential $320M milestones

## Summary
- Rigel pays $70M upfront plus up to $15M upon completion of transition activities; split evenly with Pfizer.
- Arvinas and Pfizer eligible for up to $320M in development, regulatory, and commercial milestones.
- Tiered royalties on worldwide net sales in the mid-teens to mid-20s, also split evenly.
- Rigel contributes up to $40M toward ongoing development; Arvinas/Pfizer continue current activities.
- Closing subject to HSR waiting period; NCCN added vepdegestrant as Category 2A on May 8, 2026.

## SEC filing metadata
- accession: 0001628280-26-033874
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2026-05-12T11:14:36+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/0001628280-26-033874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/arvn-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033874
- JSON: https://secwatch.observer/filing/0001628280-26-033874.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033874.txt

## Key facts
- Material Agreements
  ARVINAS, INC. entered into License Agreement with Rigel Pharmaceuticals, Inc. valued at $70.0 million (effective 2026-05-11).
  - Action: entry
  - Agreement: license
  - Counterparty: Rigel Pharmaceuticals, Inc.
  - Value: $70.0 million
  - Effective: 2026-05-11
  source text: On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000162828026033874/0001628280-26-033874-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.